arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Agenus Inc.

AGEN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$6.35
▼ -0.8% Today
as of Oct 23, 15:00 ET
Last 30 days -11.22% Sep 14 → Oct 23
$5.73 $6.86 $7.99 $9.11 $10.24 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$6.32
High
$6.52
Low
$6.24
Volume
$553,526
Avg Vol
$2M
Mkt Cap
$376M
P/E (TTM)
2.05
Beta
—
52w High
$10.31
52w Low
$2.71
Div Yield
—
Shares Out
$43M

Recent Press Releases & News last 60 days · 13 items

Oct 22 · 20:30 PR Business Wire
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Oct 20 · 21:02 MarketBeat
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
Oct 9 · 19:23 PR Business Wire
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
▸ Show all 13 press releases & news Free account →

AGEN earnings at a glance

The options market is pricing a move of about ±13.9% after the report, a range of roughly $5.47 to $7.23 from today's $6.35. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±17.5% on average; after the most recent report on May 11, 2026 it moved -14.7%. That means options currently expect less movement than AGEN has typically delivered. AGEN beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 118%. The share price of $6.35 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.71
$10
48% of range
Avg surprise (last 4)
-14.9%
Avg reaction (last 2)
+2.8%
50% positive
Latest IV / EM
118%
EM ±13.9% · $8 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-4.31$-2.65$-1.00$0.66$2.31 Actual $-4.31Actual $-3.93Actual $-3.29Actual $-3.04Actual $-2.52Actual $-3.08Actual $-1.03Est $-1.61Actual $1.00Est $-0.78Actual $1.94Est $2.31Actual $1.02Est $2.10Actual $-0.01 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-67M$-34M$-53,725$34M$67M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.01 — — — — financials
Mon May 11, 2026Mar/2026 $1.02 $2.10 -51.4% +199.0% -14.7% earnings
Mon Nov 10, 2025Sep/2025 $1.94 $2.31 -16.0% — — earnings
Mon Aug 11, 2025Jun/2025 $1.00 $-0.78 -28.2% — — earnings
Mon May 12, 2025Mar/2025 $-1.03 $-1.61 +36.0% — +20.3% earnings
Mon Sep 30, 2024Sep 2024 $-3.08 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2.52 — — — — financials
Sun Mar 31, 2024Mar 2024 $-3.04 — — — — financials
Sat Sep 30, 2023Sep 2023 $-3.29 — — — — financials
Fri Jun 30, 2023Jun 2023 $-3.93 — — — — financials
Fri Mar 31, 2023Mar 2023 $-4.31 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$35M$34M—$30M$26M$24M—$25M
Cost of revenue$0$0—$642,000$243,000$137,000—$146,000
Gross profit————————
Operating income$11M$15M—$-5M$-17M$-13M—$-32M
Net income$-567,000$39M—$64M$-30M$-26M—$-67M
EPS (diluted)$-0.01$1.02—$1.94$-1.00$-1.03—$-3.08

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$19M$35M$3M$3M$10M$18M$40M$45M
Inventory————————
Total current assets$79M$95M$133M$134M$13M$23M$46M$50M
Total assets$173M$186M$227M$234M$185M$200M$226M$238M
Long-term debt$30M$30M$45M$24M$23M$33M$30M$0
Total liabilities————————
Total equity$-199M$-228M$-271M$-274M$-336M$-322M$-326M$-272M

Implied volatility — last 90 days

59%184%309%433%558% Jun 07 — IV 140% · EM ±19.4%Jun 08 — IV 83% · EM ±11.0%Jun 09 — IV 109% · EM ±13.7%Jun 10 — IV 83% · EM ±9.8%Jun 11 — IV 127% · EM ±14.0%Jun 12 — IV 141% · EM ±14.4%Jun 15 — IV 255% · EM ±18.5%Jun 16 — IV 258% · EM ±15.3%Jun 19 — IV 83% · EM ±18.3%Jun 22 — IV 79% · EM ±16.4%Jun 24 — IV 60% · EM ±12.0%Jun 25 — IV 60% · EM ±11.7%Jun 29 — IV 99% · EM ±17.5%Jun 30 — IV 102% · EM ±17.6%Jul 01 — IV 70% · EM ±11.7%Jul 02 — IV 290% · EM ±46.9%Jul 03 — IV 211% · EM ±33.0%Jul 07 — IV 249% · EM ±32.9%Jul 08 — IV 528% · EM ±66.2%Jul 09 — IV 558% · EM ±66.0%Jul 13 — IV 268% · EM ±22.4%Jul 14 — IV 193% · EM ±13.9%Jul 15 — IV 193% · EM ±11.4%Jul 16 — IV 225% · EM ±9.4%Jul 20 — IV 132% · EM ±31.2%Jul 21 — IV 131% · EM ±30.5%Jul 22 — IV 145% · EM ±33.2%Jul 23 — IV 115% · EM ±25.9%Jul 24 — IV 134% · EM ±29.7%Jul 27 — IV 121% · EM ±25.3%Jul 28 — IV 140% · EM ±28.7%Jul 29 — IV 149% · EM ±29.8%Jul 30 — IV 138% · EM ±27.0%Jul 31 — IV 126% · EM ±24.1%Aug 03 — IV 128% · EM ±22.7%Aug 04 — IV 108% · EM ±18.7%Aug 05 — IV 119% · EM ±19.9%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 86% · EM ±13.4%Aug 10 — IV 119% · EM ±16.4%Aug 11 — IV 86% · EM ±11.3%Aug 12 — IV 116% · EM ±14.5%Aug 13 — IV 91% · EM ±10.7%Aug 14 — IV 105% · EM ±11.6%Aug 17 — IV 130% · EM ±10.8%Aug 18 — IV 157% · EM ±11.3%Aug 19 — IV 133% · EM ±7.9%Aug 20 — IV 395% · EM ±16.5%Aug 24 — IV 97% · EM ±20.3%Aug 25 — IV 111% · EM ±22.7%Aug 26 — IV 101% · EM ±20.3%Aug 27 — IV 111% · EM ±21.8%Aug 28 — IV 107% · EM ±20.6%Aug 31 — IV 106% · EM ±18.7%Sep 01 — IV 111% · EM ±19.0%Sep 02 — IV 99% · EM ±16.6%Sep 03 — IV 84% · EM ±13.7%Sep 04 — IV 78% · EM ±12.1%Sep 07 — IV 88% · EM ±12.1%Sep 08 — IV 219% · EM ±28.9%Sep 09 — IV 86% · EM ±10.8%Sep 10 — IV 127% · EM ±15.0%Sep 11 — IV 134% · EM ±14.8%Sep 14 — IV 176% · EM ±14.7%Sep 15 — IV 77% · EM ±5.6%Sep 17 — IV 249% · EM ±10.4%Sep 21 — IV 91% · EM ±18.9%Sep 22 — IV 108% · EM ±22.1%Sep 23 — IV 85% · EM ±17.0%Sep 24 — IV 96% · EM ±18.8%Sep 25 — IV 125% · EM ±24.0%Sep 28 — IV 112% · EM ±19.9%Sep 29 — IV 85% · EM ±14.7%Sep 30 — IV 99% · EM ±16.6%Oct 01 — IV 105% · EM ±17.0%Oct 02 — IV 84% · EM ±13.2%Oct 06 — IV 147% · EM ±19.4%Oct 07 — IV 95% · EM ±11.9%Oct 08 — IV 118% · EM ±13.9%

Sector peers

EDIT
Editas Medicine, Inc.
$387M $2.38-5.4%
FENC
Fennec Pharmaceuticals Inc.
$365M $10.14-2.3%
ZURA
Zura Bio Limited
$397M $3.33-19.5%
KYTX
Kyverna Therapeutics, Inc.
$403M $5.37-8.1%
CCCC
C4 Therapeutics, Inc.
$347M $3.06-3.3%
OCGN
Ocugen, Inc.
$339M $0.74-9.7%

AGEN earnings FAQ

What is AGEN's expected move for earnings?

Options currently price a move of about ±13.9%, or $0.88 per share either way from $6.35.

How does AGEN stock usually react to earnings?

Across the last 2 reports the average next-day move was ±17.5%, up 1 times and down 1 times.

What is AGEN's implied volatility?

AGEN's at-the-money implied volatility is about 118% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in